BIOMET INC Form 4

September 19, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16.

Form 4 or

obligations

Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

may continue. See Instruction

1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Jones Adrian M

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

BIOMET INC [BMET]

(First) (Middle) (Last)

(Street)

3. Date of Earliest Transaction

X_ Director 10% Owner Officer (give title Other (specify

(Check all applicable)

C/O GOLDMAN, SACHS & CO., 85 BROAD STREET

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check Applicable Line)

Filed(Month/Day/Year)

3.

(Month/Day/Year)

08/17/2007

X Form filed by One Reporting Person Form filed by More than One Reporting

below)

NEW YORK, NY 10004

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if (Instr. 3) (Month/Day/Year)

TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)

4. Securities

5. Amount of 6. Ownership 7. Nature of Securities Form: Direct Indirect Beneficially (D) or Beneficial Owned Indirect (I) Ownership Following (Instr. 4) (Instr. 4)

Ι

Reported (A) Transaction(s) or (Instr. 3 and 4)

Code V Amount (D) Price

See footnotes

Stock

Common

124,282

(1)(2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: BIOMET INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	OrD So A Or (I (I	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(2	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Security Based Swap (put equivalent)	(3)	08/17/2007		X/K			1,400	(3)	04/07/2017	Common Shares	1,400
Security Based Swap (put equivalent)	<u>(4)</u>	08/17/2007		X/K			20,200	<u>(4)</u>	04/10/2017	Common Shares	20,200
Call Option	\$ 45							<u>(5)</u>	01/17/2009	Common Shares	3,100

Reporting Owners

Reporting Owner Name / Address	Relationships						
noporomg o maor rumo, rauncos	Director	10% Owner	Officer	Other			
Jones Adrian M C/O GOLDMAN, SACHS & CO. 85 BROAD STREET NEW YORK, NY 10004	X						

Signatures

/s/ Yvette Kosic, Attorney-in-fact 09/19/2007

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person is a managing director of Goldman, Sachs & Co. ("Goldman Sachs"). Goldman Sachs is a wholly-owned subsidiary of The Goldman Sachs Group, Inc. ("GS Group"). Goldman Sachs is affiliated with private equity funds that hold equity interests in LVB Acquisition Holding, LLC, the indirect beneficial owner of 208,324,725 common shares, no par value (the "Common Shares") of Biomet, Inc. (the "Company"), including 5,723,595 Common Shares beneficially owned by Dr. Dane A. Miller and Mary Louise Miller that are subject to a voting agreement with LVB Acquisition, Inc., a subsidiary of LVB Acquisition Holding, LLC. In addition, Goldman Sachs and other wholly-owned subsidiaries of GS Group (collectively, "Goldman") may be deemed to directly

Reporting Owners 2

Edgar Filing: BIOMET INC - Form 4

beneficially own 124,282 Common Shares.

- The Reporting Person disclaims beneficial ownership of all of the securities reported on Table I and Table II of this Form 4, including the Common Shares that are or may be beneficially owned by LVB Acquisition Holding, LLC, Goldman Sachs, other wholly-owned subsidiaries of GS Group and any of their affiliated funds. The securities reported herein as indirectly beneficially owned may be deemed to be beneficially owned by Goldman.
 - On August 17, 2007, upon the accelerated settlement of a security-based swap agreement in the form of a contract for difference entered into on April 10, 2007, Goldman Sachs International ("GSI"), a wholly-owned subsidiary of GS Group, paid to its counterparty \$4,438, representing \$3.17 per share for each of 1,400 Common Shares subject to the agreement, equal to the difference between \$64,400, the price for the Common Shares on the accelerated settlement date determined with reference to the tender offer price for the Common
- (3) representing \$3.17 per share for each of 1,400 Common Shares subject to the agreement, equal to the difference between \$64,400, the price for the Common Shares on the accelerated settlement date determined with reference to the tender offer price for the Common Shares on such date and \$59,962, the price for the Common Shares when the agreement was entered into. Without admitting any legal obligation, Goldman Sachs or another wholly-owned subsidiary will remit appropriate profits, if any, to the Company.
 - On August 17, 2007, upon the accelerated settlement of a security-based swap agreement in the form of a contract for difference entered into on April 11, 2007, GSI paid to its counterparty \$63,489, representing \$3.143 per share for each of 20,200 Common Shares subject to the agreement, equal to the difference between \$929,200, the price for the Common Shares on the accelerated settlement date determined
- with reference to the tender offer price for the Common Shares on such date and \$865,711, the price for the Common Shares when the agreement was entered into. Without admitting any legal obligation, Goldman Sachs or another wholly-owned subsidiary will remit appropriate profits, if any, to the Company.
- (5) Immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.